These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22794353)

  • 21. Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme.
    Li C; Liu X; Lin X; Chen X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 34(1):20-6. PubMed ID: 19197122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design.
    Niefind K; Issinger OG
    Biochim Biophys Acta; 2010 Mar; 1804(3):484-92. PubMed ID: 19796713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refinement of X-ray data on dual cosubstrate specificity of CK2 kinase by free energy calculations based on molecular dynamics simulation.
    Setny P; Geller M
    Proteins; 2005 Feb; 58(3):511-7. PubMed ID: 15624214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Casein kinases as potential therapeutic targets.
    Cozza G; Pinna LA
    Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
    Schnitzler A; Niefind K
    Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin.
    Funakoshi-Tago M; Nakamura K; Tago K; Mashino T; Kasahara T
    Int Immunopharmacol; 2011 Sep; 11(9):1150-9. PubMed ID: 21443976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
    Gyenis L; Turowec JP; Bretner M; Litchfield DW
    Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect and its kinetic analysis of tyrphostin AG1478 on recombinant human protein kinase CK2 holoenzyme.
    Liu XG; Liang NC
    Acta Pharmacol Sin; 2002 Jun; 23(6):556-61. PubMed ID: 12060532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme].
    Liu XG; Liang NC
    Ai Zheng; 2002 Feb; 21(2):153-7. PubMed ID: 12479065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Features and potentials of ATP-site directed CK2 inhibitors.
    Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
    Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
    Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrphostins are inhibitors of guanylyl and adenylyl cyclases.
    Jaleel M; Shenoy AR; Visweswariah SS
    Biochemistry; 2004 Jun; 43(25):8247-55. PubMed ID: 15209521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Casein kinase activity in etiolated Cucumis sativus cotyledons.
    Vidal D; Alvarez-Flórez F; Simón E
    Plant Biol (Stuttg); 2010 Jan; 12(1):134-44. PubMed ID: 20653896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
    Patel S; Vyas VK; Sharma M; Ghate M
    Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2.
    Haidar S; Meyers A; Bollacke A; Jose J
    Pharmazie; 2015 Dec; 70(12):772-6. PubMed ID: 26817273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
    Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
    Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
    Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
    J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.